Eli Lilly’s weight-loss pill is on track to be FDA

Eli Lilly’s experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.

Analysts speculate that the drug, orforglipron, is a viable candidate given the growing cost burden of expensive injectable weight-loss drugs and the fact that Lilly is expanding its U.S. manufacturing – issues the Trump Administration has prioritized.

Lilly, based in Indianapolis, said the new FDA program is “a promising initiative,” but it was “too early to discuss how this submission pathway might relate to any of our specific programs.” Goldman Sachs recently estimated that if orforglipron were to launch one quarter earlier than expected, it would bring in another $1 billion in revenue t